Nasdaq grts.

Aug 4, 2022 · Second Quarter 2022 Financial Results. Cash, cash equivalents, marketable securities and restricted cash were $159.2 million as of June 30, 2022, compared to $223.5 million as of December 31, 2021 ...

Nasdaq grts. Things To Know About Nasdaq grts.

Gritstone bio, Inc. (GRTS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 1.3100 -0.0100 (-0.76%) As of 03:13PM EST. Market open. 1d 5d 1m 6m YTD 1y 5y Aug 9, 2023 · Second Quarter 2023 Financial Results. Cash, cash equivalents, marketable securities and restricted cash were $122.3 million as of June 30, 2023, compared to $185.2 million as of December 31, 2022 ... The big shareholder groups in Gritstone Oncology, Inc. (NASDAQ:GRTS) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have ...Aug 1, 2023 · Financials. GRTS has a market cap of $169mn and a cash balance of $153mn. Research and development expenses were $30.5 million for the three months ended March 31, 2023 while general and ...

May 11, 2023 · First Quarter 2023 Financial Results. Cash, cash equivalents, marketable securities and restricted cash were $153.2 million as of March 31, 2023, compared to $185.2 million as of December 31, 2022 ... Insiders seem to have made the most of their holdings by selling US$221k worth of Gritstone bio, Inc. (NASDAQ:GRTS) stock at an average sell price of US$22.10 during the past year. The company's ...Nov 10, 2023 · During the recent session, Gritstone Bio Inc (NASDAQ:GRTS)’s traded shares were 0.46 million, with the beta value of the company hitting 0.56. At the last check today, the stock’s price was $1.46, reflecting an intraday loss of -6.73% or -$0.1. The 52-week high for the GRTS share is $4.05, that ...

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.It is doubtless a positive to see that the Gritstone bio, Inc. ( NASDAQ:GRTS) share price has gained some 32% in the last three months. But that is small recompense for the exasperating returns ...

Based on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ... 24 days ago ...Gritstone bio ; Status. IPO in 2018 (NASDAQ: GRTS) ; Year of Investment. 2015 ; Strategy. Life Sciences ; Location. Bay Area, California ...Follow. EMERYVILLE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines ...Mar 8, 2022 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

(Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ... 24 days ago ...

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its ...

EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...In the last trading session, 1.12 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.61. With the company’s per share price at $1.89 changed hands at -$0.06 or -3.08% during last session, the market valuation stood at $175.92M. GRTS’s last price was a discount, traded about -114.29% off its 52 ...Gritstone bio, Inc. (NASDAQ:GRTS) is an American healthcare company that develops treatments for cancer and other diseases. It is another highly rated stock on our list since the average rating is ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone ...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.

EMERYVILLE, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer ...EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Gritstone bio ( NASDAQ: GRTS) uses its vaccine technology to promote an immune response against a patients cancer or to prevent or treat infectious disease. In late September, 2023, GRTS announced ...EMERYVILLE, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Jan 9, 2022 · Insiders seem to have made the most of their holdings by selling US$221k worth of Gritstone bio, Inc. (NASDAQ:GRTS) stock at an average sell price of US$22.10 during the past year. The company's ...

Gritstone bio, Inc. (NASDAQ:GRTS) shares rose 37% to $1.63 in pre-market trading after the company announced it was awarded a BARDA contract to conduct a Phase 2b comparative study evaluating a ...EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...

Gritstone bio, Inc. (NASDAQ:GRTS) shares rose 37% to $1.63 in pre-market trading after the company announced it was awarded a BARDA contract to conduct a Phase 2b comparative study evaluating a ...Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...On November 8, 2023, Gritstone Bio Inc ( NASDAQ:GRTS ), a clinical-stage biotechnology company, announced its financial results for the third quarter ended September 30, 2023, along with updates ...May 3, 2021 · Gritstone bio (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Management criteria checks 3/4. Gritstone bio's CEO is Andrew Allen, appointed in Aug 2015, has a tenure of 8.25 years. total yearly compensation is $2.68M, comprised of 23.2% salary and 76.8% bonuses, including company stock and options. directly owns 1.6% of the company’s shares, worth $2.07M. The average tenure of the management team and ...Gritstone bio (GRTS) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. ... GRTS: NASDAQ: Common Stock Price Change Change ...EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...May 3, 2021 · Gritstone bio (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

Oct 25, 2022 · EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...

Sep 27, 2023 · EMERYVILLE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced ...

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious …WebDec 4, 2023 · Gritstone Bio Inc (NASDAQ: GRTS)’s stock price has soared by 17.69 in relation to previous closing price of 1.30. Nevertheless, the company has seen a gain of 11.68% in its stock price over the last five trading days. Zacks Investment Research reported 2023-10-16 that Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy ... EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...(Nasdaq: GRTS), and has served as its President, Chief Executive Officer, and board member since its inception in August 2015. Prior to Gritstone, in April ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Shares of NASDAQ GRTS opened at $1.37 on Friday. The company has a market capitalization of $130.62 million, a price-to-earnings ratio of -1.10 and a beta of 0.62. The company has a debt-to-equity ...Dec 6, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone bio stock quote and GRTS charts. Latest stock price today and the US's most active stock market forums.Gritstone bio ; Status. IPO in 2018 (NASDAQ: GRTS) ; Year of Investment. 2015 ; Strategy. Life Sciences ; Location. Bay Area, California ...EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Find the latest Institutional Holdings data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...(Nasdaq: GRTS), and has served as its President, Chief Executive Officer, and board member since its inception in August 2015. Prior to Gritstone, in April ...Instagram:https://instagram. stock pldwhy is the iphone 15 cheaperis a recession coming in 2024affordable dental plans in georgia Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. books by dave ramseymilitary defense stocks Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. swing trade alerts Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Find the latest Institutional Holdings data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.